Jack West, MD, joins the podcast to discuss how he chooses first-line treatment in new patients with non–small cell lung cancer (NSCLC). Dr. West is an associate clinical professor in medical oncology at City of Hope Comprehensive Cancer Center in Duarte, Calif., and a thought leader in thoracic oncology. Dr. West also explores how the COVID-19 pandemic influences treatment approaches, the usefulness of liquid biopsy, and how he weighs the potentially higher risk for COVID-19 complications from checkpoint inhibitors. Check out Dr. West's last two appearances on the podcast: https://www.mdedge.com/podcasts/blood-cancer/immunotherapy-lung-cancer-dr-jack-west-part-1 https://www.mdedge.com/podcasts/blood-cancer/immunotherapy-lung-cancer-dr-jack-west-part-2 Disclosures: Dr. Henry reported having no financial disclosures relevant to this episode. Dr. West has a full list of his financial disclosures here. * * * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: [email protected] Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related